JP6983808B2 - 自己架橋性抗体 - Google Patents

自己架橋性抗体 Download PDF

Info

Publication number
JP6983808B2
JP6983808B2 JP2018554653A JP2018554653A JP6983808B2 JP 6983808 B2 JP6983808 B2 JP 6983808B2 JP 2018554653 A JP2018554653 A JP 2018554653A JP 2018554653 A JP2018554653 A JP 2018554653A JP 6983808 B2 JP6983808 B2 JP 6983808B2
Authority
JP
Japan
Prior art keywords
meditope
antibody
seq
available
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018554653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509054A (ja
JP2019509054A5 (https=
Inventor
ドミトル、カラン
ガーディナー、エリザベス、エム．
マッケンジー、ロバート、ピー．
マトー、マイケル、エイチ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meditope Biosciences Inc
Original Assignee
Meditope Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditope Biosciences Inc filed Critical Meditope Biosciences Inc
Publication of JP2019509054A publication Critical patent/JP2019509054A/ja
Publication of JP2019509054A5 publication Critical patent/JP2019509054A5/ja
Application granted granted Critical
Publication of JP6983808B2 publication Critical patent/JP6983808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018554653A 2016-01-08 2017-01-09 自己架橋性抗体 Expired - Fee Related JP6983808B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276803P 2016-01-08 2016-01-08
US62/276,803 2016-01-08
US201662317342P 2016-04-01 2016-04-01
US62/317,342 2016-04-01
PCT/US2017/012754 WO2017120599A1 (en) 2016-01-08 2017-01-09 Self-crosslinking antibodies

Publications (3)

Publication Number Publication Date
JP2019509054A JP2019509054A (ja) 2019-04-04
JP2019509054A5 JP2019509054A5 (https=) 2020-02-20
JP6983808B2 true JP6983808B2 (ja) 2021-12-17

Family

ID=59274084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554653A Expired - Fee Related JP6983808B2 (ja) 2016-01-08 2017-01-09 自己架橋性抗体

Country Status (8)

Country Link
US (1) US11459397B2 (https=)
EP (1) EP3399992A4 (https=)
JP (1) JP6983808B2 (https=)
KR (1) KR20180098672A (https=)
CN (1) CN108712908A (https=)
AU (1) AU2017205343A1 (https=)
CA (1) CA3010632A1 (https=)
WO (1) WO2017120599A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180105227A (ko) * 2016-02-02 2018-09-27 메디토페 바이오사이언시스, 아이엔씨. 항-egfr 항체 약물 접합체
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品（上海）有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
AU2020361622A1 (en) * 2019-10-10 2022-04-28 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic viruses that express multi-specific immune cell engagers
JP7848114B2 (ja) * 2019-10-12 2026-04-20 バイオ－セラ ソリューションズ リミテッド 抗ｃｄ２０抗体製剤及びｃｄ２０陽性疾患の治療のための抗ｃｄ２０抗体の使用
EP4071178A4 (en) * 2019-12-06 2024-10-09 Ajinomoto Co., Inc. METHOD FOR PREPARING A PEPTIDE WITH PHYSIOLOGICAL ACTIVITY AND A PEPTIDE WITH A SHORT LINKER
EP4223775A4 (en) * 2020-09-29 2025-07-30 Kunming Sinoway Natural Pharmaceuticals Co Ltd HUMANIZED RECOMBINANT ANTI-CD22 IMMUNOTOXIN AND ITS APPLICATION
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用
JPWO2022158554A1 (https=) * 2021-01-22 2022-07-28
CA3212386A1 (en) * 2021-03-18 2022-09-22 Alessandro ARCOVITO Ferritin variants with increased stability and complexation ability
CN115677856B (zh) * 2021-07-29 2023-11-28 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用
JP2024025400A (ja) * 2022-08-12 2024-02-26 浜松ホトニクス株式会社 膜貫通タンパク質を標的オルガネラに局在化させるためのペプチドリンカー及び局在化方法並びに局在化する融合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
EP1771467A2 (en) * 2004-07-26 2007-04-11 Asterion Limited Linkers
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
JP6157352B2 (ja) * 2010-10-08 2017-07-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ メディトープ（Ｍｅｄｉｔｏｐｅ）のためのモノクローナル抗体フレームワーク結合インターフェース、メディトープ送達系、およびその使用法
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN114634572A (zh) * 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
US9428553B2 (en) * 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP3200823B1 (en) * 2014-10-02 2022-11-23 City of Hope Multivalent meditopes, meditope-binding antibodies and uses thereof
EP3842448A1 (en) * 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
KR20180105227A (ko) * 2016-02-02 2018-09-27 메디토페 바이오사이언시스, 아이엔씨. 항-egfr 항체 약물 접합체

Also Published As

Publication number Publication date
EP3399992A1 (en) 2018-11-14
US20190016822A1 (en) 2019-01-17
WO2017120599A1 (en) 2017-07-13
EP3399992A4 (en) 2019-07-31
CN108712908A (zh) 2018-10-26
JP2019509054A (ja) 2019-04-04
CA3010632A1 (en) 2017-07-13
AU2017205343A1 (en) 2018-07-19
KR20180098672A (ko) 2018-09-04
US11459397B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
JP6983808B2 (ja) 自己架橋性抗体
US20230391887A1 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
JP6843816B2 (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
CN110312736B (zh) Pd-l1结合多肽或化合物
US20220098299A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
US11814441B2 (en) Bi-specific antigen-binding polypeptides
JP2025011260A (ja) 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
JP2021527429A (ja) 造血幹細胞を除去するための抗体薬物コンジュゲート
AU2024293248A1 (en) Anti-HER2 single-domain antibody, and preparation method therefor and use thereof
HK40120997A (zh) 趋化因子受体8(ccr8)抗体
HK1242589B (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
HK1242589A1 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211026

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211124

R150 Certificate of patent or registration of utility model

Ref document number: 6983808

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees